The use of immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 has already proven successful in boosting T cell responses, and combining these therapies with engineered T cells may become a standard strategy to enhance cancer immunotherapy (Kumagai et al. 2022). Here, CTLA4 is linked to cancer.